TCL Archive In Brief: New Contract To Speed Drug Development Planned; Groups To Get $5.6 Million Extra February 27, 1976
TCL Archive The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken. May 7, 2004
TCL Archive U.S. Radiologists Criticize Canadian Study Of Mammography Screening Showing No Benefit November 27, 1992
